Amid Supply Concerns, EU Approves Gilead’s Remdesivir

Despite Controversy, Blockbuster Status Predicted

Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.

EU Brussels

The European Commission has confirmed a conditional marketing authorization of Gilead Sciences Inc.’s COVID-19 therapy remdesivir, now given the brand name Veklury.

The decision comes just two days after Gilead announced that the US government had bought up nearly all of its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip